Navigation Links
Opiates Better Than Sedatives For Treating Newborns In Withdrawal

For years, sedatives have been the gold standard for treating newborns suffering from opiate withdrawal. However, new research suggests that opiates themselves are superior to sedatives for treating infants born to women who used heroin or methadone while pregnant.

Opiates appear to better "ameliorate the withdrawal, facilitate feeding and potentially reduce the likelihood of seizures," according to two new systematic reviews done by David Osborn, a neonatologist at the Royal Prince Alfred Hospital in Sydney, Australia, and colleagues.

The researchers also found that infants treated with opiates regained birth weight more quickly than those who only received supportive care.

According to their analysis, the use of opiates instead of sedatives or supportive care alone shortens the duration of supportive care by an average of four days. When compared to diazepam (Valium), opiates reduce the incidence of treatment failure.

However, infants treated with opiates had longer hospital stays than those treated with phenobarbitone, the sedative most often used in these cases. When sedatives only were compared, phenobarbitone was more likely than diazepam to reduce treatment failure.

The reviews appear in the July issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The reviews included 13 studies with a total of 890 infants of mothers who had used opiates with or without other drugs (including antidepressants, sleep aids and marijuana) during pregnancy. Researchers say two of the studies may have included identical patients.

Newborns suffering from neonatal abstinence syndrome (NAS) exhibit seizures, poor feeding, diarrhea and vomiting that lead to excessive weight loss and dehydr ation, sleeping problems and fever. Disruption in the mother-child bonding process has also been reported, and there is an increased risk of sudden infant death syndrome.

In the studies, newborns suffering from NAS were treated with opiates (morphine, methadone, paregoric, or tincture of opium), sedatives (phenobarbitone, diazepam or chlorpromazine) or supportive care only. None of the studies compared opiate treatment with placebo.

Of the randomized and "quasi-random" studies analyzed, "the evidence is not high quality," Osborn says, and unanswered questions remain. For example, in infants treated with an opiate, the addition of phenobarbitone may reduce withdrawal severity, but more research is needed using a higher initial dose of opiate, and to examine the effects of phenobarbitone on infant development.

In the 1999 U.S. National Household Survey on Drug Abuse, 3.4 percent of pregnant women reported illicit drug use in the past month, which according to authors represents some 3,000 current pregnant heroin users in the U.S., similar to Australian figures. Between 48 percent and 94 percent of infants exposed to opiates in the uterus develop clinical signs of withdrawal

"The interesting information," Osborn says, "suggests that these infants can be treated without admission to the special care nursery unless withdrawal is complicated and that this is facilitated by use of morphine instead of phenobarbitone. This helps keep mothers and babies together, helps in educating the mothers in mothercraft skills and to recognize signs of infant withdrawal, and helps in assessment of the quality of the mother-infant interaction in a supervised environment."


'"/>

Source:Center for the Advancement of Health


Related biology news :

1. Institute for Systems Biology Symposium Addresses Need for Better Computational Tools
2. Protein Discovery Could Unlock The Secret To Better TB Treatment
3. Computational Tool Predicts How Drugs Work In Cells, Advancing Efforts To Design Better Medicines
4. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
5. Better beetle sought for salt cedar control
6. Better sludge through metagenomics
7. Better assessment of transfusions could save blood
8. Better health twice as likely for nonsmokers who live and work with smoking restrictions
9. Potential Drug Target For Treating Cocaine Abuse Found
10. NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma
11. Treating populations infected with HIV and latent TB could speed the emergence of drug-resistant TB
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/3/2017)... VEGAS , Jan. 3, 2017 Onitor, ... the introduction of Onitor Track, an innovative biometric data-driven ... men, showcasing this month at the 2017 Consumer Electronics ... In the U.S., the World Health ... more than two-thirds of adults who are overweight or ...
(Date:12/22/2016)... , December 22, 2016 SuperCom ... of secure solutions for the e-Government, Public Safety, HealthCare, and Finance ... of SuperCom, has been selected to implement and deploy a community-based ... Northern California , further expanding its presence in ... This ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical trial ... of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The ... percent of these heavily pretreated patients saw clinical benefit from the drug, with ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... announced today that the National Science Foundation (NSF) has awarded Symbios a ... will be used to commercialize the Symbios Tubular Plasma Reactor™ (TPR™) by scaling ...
(Date:1/11/2017)... , Jan. 11, 2017  GenVec, Inc. ... delivery company, announced today that its chief scientific ... a talk entitled  "AdenoVerse™ platform for translational development ... Biotech Showcase at the upcoming Phacilitate Cell & ... Miami , Florida.  Dr. Brough,s presentation will ...
Breaking Biology Technology: